Biotech Transparency Law Fails to Alter Patent Negotiation Strategies, Legal Experts Observed

In the three years since the introduction of a law aimed at increasing transparency in patent information exchanges among biologic and biosimilar manufacturers, industry practices have shown little change. The anticipated strategic withholding of information has not materialized, leaving many legal experts taken aback by the apparent consistency in these companies’ approaches to patent negotiations. For professionals engaged in the biotech sector, the implications suggest a steadier landscape than was initially projected. The law, which encourages the public disclosure of patent data, aimed to foster an environment of transparency, yet companies operating in this space have largely maintained their pre-existing strategies. For more details on this development, visit Law360.